Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma

Giorgio Scagliotti

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial evaluating the combination of chemotherapy and gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), as first-line treatment for patients with advanced lung adenocarcinoma and activating EGFR mutations.

Share this video  
Similar topics
Related videos
3:58
Issues with treating late cancer effects from pediatric cancer
Carina Schneider
1:29
How can durvalumab be used in NSCLC?
Sanjay Popat
1:56
ECCO 2017: important trials in bladder cancer and renal cell carcinoma
Laurence Albiges
4:47
Mesothelioma surgical trial updates in the UK: MARS2 and MesoTRAP
Robert Rintoul
3:24
Interesting topics presented at ESMO 2017
Fatima Cardoso
Lung Cancer
Gefitinib
ELCC 2016
Interview
15th April 2016
More from Giorgio Scagliotti
The importance of precision immunotherapy: cost, benefit & toxicity
Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC
Immunotherapy in NSCLC: a perspective
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals